Tycel Phillips, MD, City of Hope, Duarte, CA, discusses the results of a study evaluating the safety and efficacy of acalabrutinib in combination with bendamustine and rituximab (ABR) in patients with treatment-naïve or relapsed/refractory (R/R) mantle cell lymphoma (MCL). This triplet combination was well tolerated and effective, and is being further investigated in Phase III trials. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть